{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029022","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.229206+00:00","generated_at":"2026-06-18T11:50:04.993906+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edgewise Therapeutics appoints Dr. Jonathan Fox to board of directors","bullets":["Dr. Jonathan Fox appointed as Class III director, term expiring at 2024 annual meeting.","He is President and CMO of BridgeBio Pharma and former CMO of MyoKardia, inventor of Camzyos.","Compensation includes $38k annual cash retainer, $4k for Nominating Committee, and stock option with ~$300k grant date fair value.","Company plans to advance EDG-7500 towards Phase 1 trial in HCM in H2 2023.","No arrangements or transactions requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029022","json":"https://secwatch.observer/filing/0001104659-23-029022.json","markdown":"https://secwatch.observer/filing/0001104659-23-029022.md","text":"https://secwatch.observer/filing/0001104659-23-029022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/0001104659-23-029022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/tm238572d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:50:04.993906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f6de0b122","claim":"Dr. Jonathan Fox was appointed as Director at Edgewise Therapeutics, Inc..","evidence_excerpt":"On March 2, 2023, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Dr. Jonathan Fox to serve (i) as a Class III director, with a term expiring at the Company’s 2024 annual meeting of stockholders, and (ii) as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000110465923029022/0001104659-23-029022-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}